FSHD1 or FSHD2: That is the question
The answer: It's all just FSHD
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Facioscapulohumeral muscular dystrophy (FSHD) is the 3rd most common form of muscular dystrophy. While the initial pattern of muscle involvement is familiar to most clinicians (facial weakness, scapular winging, and foot drop), the genetic mechanism likely is not and is unique for the dystrophies, with epigenetic de-repression playing a key role. Epigenetic repression is the mechanism by which our cells turn sections of our DNA off. If you think of our chromosomes like a series of cookbooks, and the genes like recipes, then the way we regulate which recipes are read is by epigentic repression, which in the cell is done by methylation or other chemical mechanisms. Highly methylated areas are turned off; this would be like a book in a store still shrink-wrapped in plastic, so you cannot read what is inside. Each area of the DNA can be separately regulated, and genes whose role is DNA methylation are called chromatin repressors. Most individuals (>95%) will have FSHD type 1 (FSHD1), due to a deletion of large repeated units (RU) on the long arm of chromosome 4, typically between 1 and 10 RU.1 A minority of individuals will have FSHD type 2 (FSHD2): these individuals show digenic inheritance and have associated mutations in genes that have a role in chromatin repression (SMCHD1, DNMT3B).2,3 The unified model for FSHD both emphasizes the epigenetic nature of FSHD and provides a link between FSHD1 and 2.4 In both FSHD type 1 and 2, there is decreased methylation in the D4Z4 region: in FSHD1 due to deletion of RU and in FSHD2 due to mutations affecting genes responsible for DNA methylation. To return to the cookbook metaphor, decreasing methylation on the DNA is like ripping the plastic shrink-wrap off the book, so now the recipes inside can be read. In addition to the epigenetic changes, both FSHD types 1 and 2 also require a permissive polymorphism providing a polyadenylation sequence to the DUX4 transcript (4qA allele). At its simplest level, FSHD is due to a toxic gain-of-function, where a gene contained in the D4Z4 repeats and is normally silenced, DUX4, gets “turned on,” which is toxic to cells.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See page 891
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sharon Poisson and Dr. Tiffany Brown
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
FSHD1 and FSHD2 form a disease continuumSabrina Sacconi, Audrey Briand-Suleau, Marilyn Gros et al.Neurology, April 12, 2019 -
Article
A family-based study into penetrance in facioscapulohumeral muscular dystrophy type 1Mariëlle Wohlgemuth, Richard J. Lemmers, Marianne Jonker et al.Neurology, July 11, 2018 -
Article
Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophyKohei Hamanaka, Darina Šikrová, Satomi Mitsuhashi et al.Neurology, May 28, 2020 -
Article
A focal domain of extreme demethylation within D4Z4 in FSHD2Lynn M. Hartweck, Lindsey J. Anderson, Richard J. Lemmers et al.Neurology, January 02, 2013


